This company listing is no longer active
Abliva Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Ellen Donnelly
Chief executive officer
SEK 5.5m
Total compensation
| CEO salary percentage | 56.83% |
| CEO tenure | 2.2yrs |
| CEO ownership | n/a |
| Management average tenure | 7.3yrs |
| Board average tenure | 5.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2022 | SEK 6m | SEK 3m | -SEK 85m |
| Sep 30 2022 | n/a | n/a | -SEK 105m |
| Jun 30 2022 | n/a | n/a | -SEK 114m |
| Mar 31 2022 | n/a | n/a | -SEK 124m |
| Dec 31 2021 | SEK 4m | SEK 2m | -SEK 123m |
Compensation vs Market: Ellen's total compensation ($USD534.69K) is above average for companies of similar size in the UK market ($USD348.41K).
Compensation vs Earnings: Ellen's compensation has increased whilst the company is unprofitable.
CEO
Ellen Donnelly (48 yo)
Dr. Ellen K. Donnelly, Ph D has been Chief Executive Officer at Abliva AB (publ) since February 03, 2021. She serves as Independent Director at Modus Therapeutics Holding Ab since 2020.Dr. Donnelly has be...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 2.2yrs | SEK 5.53m | no data | |
| Deputy CEO | 9.3yrs | no data | 0.017% SEK 41.9k | |
| Chief Scientific Officer & VP of Discovery | 23.3yrs | SEK 247.00k | no data | |
| Director of Communications | 5.5yrs | no data | no data | |
| Chief Medical Officer and VP of Preclinical & Clinical Development | 7.3yrs | no data | no data | |
| Consultant | no data | no data | no data |
Experienced Management: ABLIS's management team is seasoned and experienced (7.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Director | less than a year | no data | no data | |
| Chairman of the Board | 7yrs | SEK 463.00k | no data | |
| Director | 6.3yrs | SEK 460.00k | no data | |
| Director | 6.3yrs | SEK 421.00k | no data | |
| Director | 5yrs | SEK 447.00k | no data | |
| Director | 2.8yrs | no data | 15.15% SEK 36.4m |
Experienced Board: ABLIS's board of directors are considered experienced (5.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/04/15 16:05 |
| End of Day Share Price | 2023/01/16 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Abliva AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Patrik Ling | DNB Carnegie |
| Jonas Peciulis | Edison Investment Research |
| Niklas Elmhammer | Redeye |